Novartis AG ADR Asset Resilience Ratio
Novartis AG ADR asset resilience ratio. Novartis AG ADR (NVS) has an Asset Resilience Ratio of 0.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Novartis AG ADR liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Novartis AG ADR (1998–2025)
Asset resilience ratio of Novartis AG ADR from 1998 to 2025. This chart shows how Novartis AG ADR's Asset Resilience Ratio has changed over time. Read Novartis AG ADR balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Novartis AG ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NVS asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $74.00 Million | 0.06% |
| Total Liquid Assets | $74.00 Million | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Novartis AG ADR maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novartis AG ADR Industry Peers by Asset Resilience Ratio
Compare Novartis AG ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Novartis AG ADR Asset Resilience Ratio by Year (1998–2025)
Novartis AG ADR asset resilience ratio by year from 1998 to 2025. The table below shows the annual Asset Resilience Ratio data for Novartis AG ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.80% | $9.01 Billion | $115.57 Billion | -2.73pp |
| 2024-12-31 | 10.53% | $10.77 Billion | $102.25 Billion | -0.23pp |
| 2023-12-31 | 10.76% | $10.76 Billion | $99.94 Billion | -2.64pp |
| 2022-12-31 | 13.40% | $15.74 Billion | $117.45 Billion | -5.35pp |
| 2021-12-31 | 18.75% | $24.72 Billion | $131.79 Billion | +12.84pp |
| 2020-12-31 | 5.91% | $7.81 Billion | $132.19 Billion | -1.01pp |
| 2019-12-31 | 6.92% | $8.20 Billion | $118.41 Billion | -1.90pp |
| 2018-12-31 | 8.82% | $12.84 Billion | $145.56 Billion | +3.93pp |
| 2017-12-31 | 4.90% | $6.51 Billion | $133.08 Billion | +0.39pp |
| 2016-12-31 | 4.51% | $5.87 Billion | $130.12 Billion | +3.92pp |
| 2015-12-31 | 0.59% | $773.00 Million | $131.56 Billion | -0.08pp |
| 2014-12-31 | 0.67% | $839.00 Million | $125.39 Billion | -1.34pp |
| 2013-12-31 | 2.01% | $2.54 Billion | $126.25 Billion | -0.06pp |
| 2012-12-31 | 2.07% | $2.57 Billion | $124.22 Billion | +0.90pp |
| 2011-12-31 | 1.16% | $1.37 Billion | $117.50 Billion | -1.12pp |
| 2010-12-31 | 2.28% | $2.81 Billion | $123.32 Billion | -12.96pp |
| 2009-12-31 | 15.24% | $14.55 Billion | $95.50 Billion | +10.03pp |
| 2008-12-31 | 5.21% | $4.08 Billion | $78.30 Billion | -5.18pp |
| 2007-12-31 | 10.39% | $7.84 Billion | $75.45 Billion | +4.30pp |
| 2006-12-31 | 6.09% | $4.14 Billion | $68.01 Billion | -1.90pp |
| 2005-12-31 | 7.99% | $4.61 Billion | $57.73 Billion | -7.63pp |
| 2004-12-31 | 15.62% | $8.51 Billion | $54.47 Billion | +0.19pp |
| 2003-12-31 | 15.44% | $7.61 Billion | $49.32 Billion | +0.46pp |
| 2002-12-31 | 14.98% | $6.76 Billion | $45.14 Billion | -1.04pp |
| 2001-12-31 | 16.02% | $6.46 Billion | $40.30 Billion | -4.12pp |
| 2000-12-31 | 20.14% | $7.15 Billion | $35.48 Billion | +4.81pp |
| 1999-12-31 | 15.33% | $6.32 Billion | $41.21 Billion | +3.82pp |
| 1998-12-31 | 11.52% | $4.63 Billion | $40.21 Billion | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more